ClinicalTrials.gg
CompletedNCT02648048ISLAND2Updated Oct 30, 2017

A Study of Oral Vismodegib in Combination With Pirfenidone in Participants With Idiopathic Pulmonary Fibrosis

A Phase 1 interventional study of Pirfenidone and Vismodegib in Idiopathic Pulmonary Fibrosis, sponsored by Hoffmann-La Roche. Completed at 15 sites in 2 countries. Open to participants aged 40 Years to 80 Years. Per ClinicalTrials.gov, last updated 2017-10-30.

Sponsored by Hoffmann-La Roche · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
21
Allocation
Not applicable
Ages
40 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis — 2 open to participants now, 3 under way, 1 of them phase 3. pirfenidone · Idiopathic Pulmonary Fibrosis.

Enrollment
20th of 21
21 · median 89
Started
2016
with 2 others
Phase 1
5 of 21
none open now
Registered
11th of 21
by date
Lead sponsor
4 of 21
Hoffmann-La Roche

Among the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, this one is the 20th largest by enrollment, is one of 3 that started in 2016, is one of 5 in phase 1, and was the 11th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

2 of the 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis are open now, in 3 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 2 open studies →

About pirfenidone

pirfenidone: first FDA approval 2014 (ESBRIET), first EMA approval 2011. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies testing pirfenidone in Idiopathic Pulmonary Fibrosis, or all of them as a file.
02

Study summary

This is a single arm, multicenter, open-label, Phase 1b study to evaluate the safety and tolerability of vismodegib in combination with pirfenidone in participants with idiopathic pulmonary fibrosis (IPF) currently being treated with pirfenidone.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis

Keywords

  • Idiopathic Pulmonary Fibrosis
  • Vismodegib
  • Pirfenidone
04

Who can participate

Ages eligible
40 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Have a diagnosis of IPF 5 years from time of screening, confirmed at baseline
  • Tolerated dose of pirfenidone 1602-2403 mg once daily (QD) for a minimum of 24 weeks required prior to and during screening
  • Greater than or equal to (>=) 50 percent (%) and less than or equal to (\<=) 100% of predicted forced vital capacity (FVC) at screening
  • Stable baseline lung function as evidenced by a difference of less than (\<) 10% in absolute FVC measurements (in liters) between screening and Day 1/Visit 2 prior to enrollment
  • >=30% and \<=90% of predicted diffusion capacity of the lung for carbon monoxide at screening
  • Agree to use protocol defined methods of
  • Male participants must agree not to donate semen during the study and for at least 2 months (or as per local requirements) after the last dose of vismodegib
  • Agree not to donate blood or blood products during the study and for at least 9 months (or as per local requirements) after the last dose of study treatment

Exclusion criteria

Exclusion Criteria:

  • Prior treatment with vismodegib or any Hh-pathway inhibitor
  • Evidence of other known causes of interstitial lung disease
  • Hospitalization due to an exacerbation of IPF within 4 weeks prior to or during screening
  • Lung transplant expected within 6 months of screening
  • Evidence of lung disease other than IPF
  • Post-bronchodilator /FVC ratio \<0.7 at screening
  • Any clinically significant medical disease (other than IPF) that is associated with an expected survival of \<6 months, likely to require a change in therapy during the study
  • Class IV chronic heart failure or historical evidence of \<35%
  • Known current or current evaluation for a potential malignancy
  • Known immunodeficiency, including, but not limited to, infection
  • Evidence of acute or chronic hepatitis or known liver cirrhosis
  • \<=30 milliliter per minute, calculated using the Cockcroft-Gault formula
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
21 participants (actual)

Study arms

  • Experimental
    Vismodegib and Pirfenidone

    Participants being treated with pirfenidone, will receive vismodegib 150 milligrams (mg) once daily and pirfenidone up to 2403 mg daily orally for 24 weeks.

    Drug: Pirfenidone · Drug: Vismodegib

Interventions

  • Pirfenidone will be administered as per the dosage schedule mentioned in arm description.

    Also known as: RO0220912

  • Vismodegib will be administered as per the dosage schedule mentioned in arm description.

    Also known as: RO5450815

06

What researchers measure

Primary outcomes

  1. Percentage of Participants with Serious and Non-Serious Adverse Events

    An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship. A serious adverse event is an adverse event resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly.

    Time frame: Baseline up to 28 weeks

  2. Percentage of Participants with Discontinuation of Any Study Medication Due to a Drug-Related Adverse Event

    An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship. Relatedness to the study drug will be assessed by the investigator.

    Time frame: Baseline up to 28 weeks

  3. Percentage of Participants with Dose Modifications Due to Laboratory Abnormalities and Adverse Events

    An adverse event is any untoward medical occurrence in a participant who receive study drug without regard to possibility of causal relationship.

    Time frame: Baseline up to 28 weeks

  4. Percentage of Participants with Clinically Meaningful Laboratory Abnormalities as Assessed by Investigator

    Vital signs and laboratory parameters will be evaluated, and percentage of participants with any clinically meaningful abnormalities as assessed by Investigator will be reported. Laboratory abnormalities of National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) Grade greater than (\>) 3 will be considered clinical meaningful.

    Time frame: Baseline up to 28 weeks

Secondary outcomes

  1. Total and Free Trough Plasma Concentrations of Vismodegib at Week 4 (Cmin, Wk4)

    Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + alpha-1-acid glycoprotein (AAG)-bound vismodegib plasma concentration.

    Time frame: Predose (0 hour) at Week 4

  2. Total and Free Trough Plasma Concentrations of Vismodegib at Week 12 (Cmin, Wk12)

    Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.

    Time frame: Predose (0 hour) at Week 12

  3. Total and Free Trough Plasma Concentrations of Vismodegib at Week 24 (Cmin, Wk24)

    Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.

    Time frame: Predose (0 hour) at Week 24

  4. Total and Free Trough Plasma Concentrations of Vismodegib at Safety Follow-up Visit (Cmin, SFU)

    Total plasma concentration of vismodegib = free (unbound) vismodegib plasma concentration + AAG-bound vismodegib plasma concentration.

    Time frame: At Day 30 post last dose (last dose = 24 weeks) (up to 28 weeks)

07

Study locations

15 sites
  • Scripps Clinic
    La Jolla, California 92037, United States
  • Central Florida Pulmonary Group, PA
    Orlando, Florida 32803, United States
  • Suburban Lung Associates
    Elk Grove, Illinois 60007, United States
  • Medical Consultants, PC ; Pulmonary
    Muncie, Indiana 47303, United States
  • University of Louisville
    Louisville, Kentucky 40202-1798, United States
  • Tulane University Medical School
    New Orleans, Louisiana 70112, United States
  • Steward St. Elizabeth's Medical Center ; Pulmonary, Critical Care and Sleep Medicine
    Boston, Massachusetts 02135, United States
  • Creighton University Medical Center
    Omaha, Nebraska 68131, United States
  • Allied Clinical Research
    Reno, Nevada 89503, United States
  • Atlantic Respiratory Institute
    Summit, New Jersey 07901, United States
  • Pulmonix LLC
    Greensboro, North Carolina 27403, United States
  • PMG Research of Wilmington
    Wilmington, North Carolina 28401, United States
  • Western Washington Medical Group
    Everett, Washington 98208, United States
  • Swedish Medical Center
    Seattle, Washington 98122, United States
  • Fraunhofer-Institut fur Toxikologie und Experimentelle Medizin ITEM
    Hannover, 30625, Germany
08

References and documents

Publications

  • Prasse A, Ramaswamy M, Mohan S, Pan L, Kenwright A, Neighbors M, Belloni P, LaCamera PP. A Phase 1b Study of Vismodegib with Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis. Pulm Ther. 2019 Dec;5(2):151-163. doi: 10.1007/s41030-019-0096-8. Epub 2019 Jul 19. PubMed 32026407 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jan 2016 to primary completion in Nov 2016, 10 months.

Of 60 industry-sponsored phase 1 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 10 months is close to that.

Counting every sponsor, half of 75 studies reached it within 12 months; a quarter within 5 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2016
First posted
Jan 6, 2016
StartActual
Jan 15, 2016
Primary completionActual
Nov 30, 2016
CompletionActual
Nov 30, 2016
Last update
Oct 30, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02648048
Lead sponsor
Hoffmann-La Roche
Responsible party
Sponsor
First posted
Jan 6, 2016
Start date
Jan 15, 2016
Primary completion
Nov 30, 2016
Completion
Nov 30, 2016
Last update
Oct 30, 2017

Study contacts

Clinical Trials
study director · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Pirfenidone · HhAntag691

Start the discussion